日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Initial-site characterization of hydrogen migration following strong-field double-ionization of ethanol

乙醇强场双电离后氢迁移的初始位点表征

Severt, Travis; Weckwerth, Eleanor; Kaderiya, Balram; Feizollah, Peyman; Jochim, Bethany; Borne, Kurtis; Ziaee, Farzaneh; P, Kanaka Raju; Carnes, Kevin D; Dantus, Marcos; Rolles, Daniel; Rudenko, Artem; Wells, Eric; Ben-Itzhak, Itzik

A reporter Oropouche virus expressing ZsGreen from the M segment enables pathogenesis studies in mice

一种表达M片段ZsGreen的报告基因Oropouche病毒可用于小鼠致病机制研究。

Krista Gunter ,Dorcus Omoga ,James M Bowen ,Lorimar Robledo Gonzalez ,Sydney Severt ,Mackenzie Davis ,Megan Szymanski ,George Sandusky ,W Paul Duprex ,Natasha L Tilston-Lunel

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

阿托格泮用于预防性偏头痛治疗对随机、双盲、3期ADVANCE试验中患者报告结局的影响

Lipton, Richard B; Pozo-Rosich, Patricia; Blumenfeld, Andrew M; Li, Ye; Severt, Lawrence; Stokes, Jonathan T; Creutz, Lela; Gandhi, Pranav; Dodick, David

Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial

每日一次口服阿托格泮用于偏头痛的长期预防性治疗:一项多中心、随机、开放标签的3期试验结果

Ashina, Messoud; Tepper, Stewart J; Reuter, Uwe; Blumenfeld, Andrew M; Hutchinson, Susan; Xia, Jing; Miceli, Rosa; Severt, Lawrence; Finnegan, Michelle; Trugman, Joel M

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial

阿托格泮用于成人偏头痛预防的反应率:一项随机临床试验的二次分析

Lipton, Richard B; Pozo-Rosich, Patricia; Blumenfeld, Andrew M; Dodick, David W; McAllister, Peter; Li, Ye; Lu, Kaifeng; Dabruzzo, Brett; Miceli, Rosa; Severt, Lawrence; Finnegan, Michelle; Trugman, Joel M

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

阿托格泮预防性治疗偏头痛的疗效时间进程:来自随机、双盲 ADVANCE 试验的结果

Schwedt, Todd J; Lipton, Richard B; Ailani, Jessica; Silberstein, Stephen D; Tassorelli, Cristina; Guo, Hua; Lu, Kaifeng; Dabruzzo, Brett; Miceli, Rosa; Severt, Lawrence; Finnegan, Michelle; Trugman, Joel M

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials

Ubrogepant 对同时服用偏头痛预防药物的受试者安全有效:一项 3 期试验的汇总分析

Blumenfeld, Andrew M; Knievel, Kerry; Manack Adams, Aubrey; Severt, Lawrence; Butler, Matthew; Lai, Hongxin; Dodick, David W

Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia

成人起病的特发性、孤立性、局灶性颈肌张力障碍的非运动表型亚组

Wadon, Megan E; Bailey, Grace A; Yilmaz, Zehra; Hubbard, Emily; AlSaeed, Meshari; Robinson, Amy; McLauchlan, Duncan; Barbano, Richard L; Marsh, Laura; Factor, Stewart A; Fox, Susan H; Adler, Charles H; Rodriguez, Ramon L; Comella, Cynthia L; Reich, Stephen G; Severt, William L; Goetz, Christopher G; Perlmutter, Joel S; Jinnah, Hyder A; Harding, Katharine E; Sandor, Cynthia; Peall, Kathryn J

Examining key hotel attributes for guest sleep and overall satisfaction

分析影响客人睡眠和整体满意度的关键酒店属性

Robbins, Rebecca; Grandner, Michael; Knowlden, Adam; Severt, Kimberly

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial

Ubrogepant治疗急性偏头痛的长期安全性评价:3期随机52周扩展试验

Ailani, Jessica; Lipton, Richard B; Hutchinson, Susan; Knievel, Kerry; Lu, Kaifeng; Butler, Matthew; Yu, Sung Yun; Finnegan, Michelle; Severt, Lawrence; Trugman, Joel M